Literature DB >> 25178503

Decade in review--heart failure: 10 Years of progress in HF research--what have we learned?

Henry Krum1.   

Abstract

In this Decade in Review article, I highlight the top 10 advances in heart failure (HF) over the past decade, including new pharmacological therapies and expanded indications for devices in HF with reduced ejection fraction.The poor progress in acute HF and HF with preserved ejection fraction is emphasised. Biomarkers and devices that help prevent, detect, and guide treatment represent the future of HF management.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25178503     DOI： 10.1038/nrcardio.2014.127

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


  10 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure.

Authors:  Mariell Jessup; Barry Greenberg; Donna Mancini; Thomas Cappola; Daniel F Pauly; Brian Jaski; Alex Yaroshinsky; Krisztina M Zsebo; Howard Dittrich; Roger J Hajjar
Journal:  Circulation       Date:  2011-06-27       Impact factor: 29.690

3.  Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

Authors:  John R Teerlink; Gad Cotter; Beth A Davison; G Michael Felker; Gerasimos Filippatos; Barry H Greenberg; Piotr Ponikowski; Elaine Unemori; Adriaan A Voors; Kirkwood F Adams; Maria I Dorobantu; Liliana R Grinfeld; Guillaume Jondeau; Alon Marmor; Josep Masip; Peter S Pang; Karl Werdan; Sam L Teichman; Angelo Trapani; Christopher A Bush; Rajnish Saini; Christoph Schumacher; Thomas M Severin; Marco Metra
Journal:  Lancet       Date:  2012-11-07       Impact factor: 79.321

4.  Spironolactone for heart failure with preserved ejection fraction.

Authors:  Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

5.  Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial.

Authors:  Mark Ledwidge; Joseph Gallagher; Carmel Conlon; Elaine Tallon; Eoin O'Connell; Ian Dawkins; Chris Watson; Rory O'Hanlon; Margaret Bermingham; Anil Patle; Mallikarjuna R Badabhagni; Gillian Murtagh; Victor Voon; Leslie Tilson; Michael Barry; Laura McDonald; Brian Maurer; Kenneth McDonald
Journal:  JAMA       Date:  2013-07-03       Impact factor: 56.272

6.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

7.  Ferric carboxymaltose in patients with heart failure and iron deficiency.

Authors:  Stefan D Anker; Josep Comin Colet; Gerasimos Filippatos; Ronnie Willenheimer; Kenneth Dickstein; Helmut Drexler; Thomas F Lüscher; Boris Bart; Waldemar Banasiak; Joanna Niegowska; Bridget-Anne Kirwan; Claudio Mori; Barbara von Eisenhart Rothe; Stuart J Pocock; Philip A Poole-Wilson; Piotr Ponikowski
Journal:  N Engl J Med       Date:  2009-11-17       Impact factor: 91.245

8.  Cardiac-resynchronization therapy for the prevention of heart-failure events.

Authors:  Arthur J Moss; W Jackson Hall; David S Cannom; Helmut Klein; Mary W Brown; James P Daubert; N A Mark Estes; Elyse Foster; Henry Greenberg; Steven L Higgins; Marc A Pfeffer; Scott D Solomon; David Wilber; Wojciech Zareba
Journal:  N Engl J Med       Date:  2009-09-01       Impact factor: 91.245

Review 9.  Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis.

Authors:  Richard W Troughton; Christopher M Frampton; Hans-Peter Brunner-La Rocca; Matthias Pfisterer; Luc W M Eurlings; Hans Erntell; Hans Persson; Christopher M O'Connor; Deddo Moertl; Patric Karlström; Ulf Dahlström; Hanna K Gaggin; James L Januzzi; Rudolf Berger; A Mark Richards; Yigal M Pinto; M Gary Nicholls
Journal:  Eur Heart J       Date:  2014-03-06       Impact factor: 29.983

10.  Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF).

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  Eur J Heart Fail       Date:  2014-06-03       Impact factor: 15.534
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.